This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Olsen, E. Articles by Nichols, J. Search for Related Content PubMed PubMed Citation Articles by Olsen, E. Articles by Nichols, J. Social Bookmarking                            What's this?

Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma

From the Duke University Medical Center, Durham, NC; University of Texas Anderson Cancer Center, Houston, and University of Texas Health Sciences Center at San Antonio, San Antonio, TX; Hollings Cancer Center, Charleston, SC; Stanford University, Stanford, University of California Los Angeles, Los Angeles, and City of Hope, Duarte, CA; Washington University, St Louis, MO; Allegheny University, Philadelphia, and University of Pittsburgh, Pittsburgh, PA; University Hospital of Cleveland, Cleveland, OH; Indiana University, Indianapolis, IN; Yale University, New Haven, CT; Roswell Park Cancer Institute, Buffalo, and Columbia Presbyterian, New York, NY; University of Michigan, Ann Arbor, and Henry Ford Health System, Detroit, MI; Northwestern University Medical School, Chicago, IL; Boston University Medical Center, Boston, and Seragen, Inc, Hopkinton, MA; University of Colorado, Denver, CO; and Vanderbilt University, Nashville, TN.

Address reprint requests to Elise A. Olsen, MD, Duke University Medical Center, Box 3294, Durham, NC 27710; email olsen001{at}mc.duke.edu

PURPOSE: The objective of this phase III study was to determine the efficacy, safety, and pharmacokinetics of denileukin diftitox (DAB₃₈₉IL-2, Ontak [Ligand Phar-maceuticals Inc, San Diego, CA]) in patients with stage Ib to IVa cutaneous T-cell lymphoma (CTCL) who have previously received other therapeutic interventions.

PATIENTS AND METHODS: Patients with biopsy-proven CTCL that expressed CD25 on 20% of lymphocytes were assigned to one of two dose levels (9 or 18 µg/kg/d) of denileukin diftitox administered 5 consecutive days every 3 weeks for up to 8 cycles. Patients were monitored for toxicity and clinical efficacy, the latter assessed by changes in disease burden and quality of life measurements. Antibody levels of antidenileukin diftitox and anti–interleukin-2 and serum concentrations of denileukin diftitox were also measured.

RESULTS: Overall, 30% of the 71 patients with CTCL treated with denileukin diftitox had an objective response (20% partial response; 10% complete response). The response rate and duration of response based on the time of the first dose of study drug for all responders (median of 6.9 months with a range of 2.7 to more than 46.1 months) were not statistically different between the two doses. Adverse events consisted of flu-like symptoms (fever/chills, nausea/vomiting, and myalgias/arthralgias), acute infusion-related events (hypotension, dyspnea, chest pain, and back pain), and a vascular leak syndrome (hypotension, hypoalbuminemia, edema). In addition, 61% of the patients experienced transient elevations of hepatic transaminase levels with 17% grade 3 or 4. Hypoalbuminemia occurred in 79%, including 15% with grade 3 or 4 changes. Tolerability at 9 and 18 µg/kg/d was similar, and there was no evidence of cumulative toxicity.

CONCLUSION: Denileukin diftitox has been shown to be a useful and important agent in the treatment of patients whose CTCL is persistent or recurrent despite other therapeutic interventions.

None of the authors have equity interests in Seragen with the exception of P.B. and J.N.. Seragen, Inc is a wholly owned subsidiary of Ligand Pharmaceuticals Inc, San Diego, CA. Seragen holds the license for Ontak.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. K. Gopal, J. M. Pagel, J. R. Fromm, S. Wilbur, and O. W. Press 131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma Blood, June 4, 2009; 113(23): 5905 - 5910. [Abstract] [Full Text] [PDF]

				J. T. Sandlund Clinical Features and Treatment Approaches for the Uncommon Non-Hodgkin Lymphoma Subtypes in Children ASCO Educational Book, January 1, 2009; 2009(1): 598 - 603. [Abstract] [Full Text] [PDF]

				Y. Zhang and I. Pastan High Shed Antigen Levels within Tumors: An Additional Barrier to Immunoconjugate Therapy Clin. Cancer Res., December 15, 2008; 14(24): 7981 - 7986. [Abstract] [Full Text] [PDF]

				M. A. Morse, A. C. Hobeika, T. Osada, D. Serra, D. Niedzwiecki, H. K. Lyerly, and T. M. Clay Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines Blood, August 1, 2008; 112(3): 610 - 618. [Abstract] [Full Text] [PDF]

				L. Ellis, Y. Pan, G. K. Smyth, D. J. George, C. McCormack, R. Williams-Truax, M. Mita, J. Beck, H. Burris, G. Ryan, et al. Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma Clin. Cancer Res., July 15, 2008; 14(14): 4500 - 4510. [Abstract] [Full Text] [PDF]

				M. Kioi, S. Seetharam, and R. K. Puri Targeting IL-13R{alpha}2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin Mol. Cancer Ther., June 1, 2008; 7(6): 1579 - 1587. [Abstract] [Full Text] [PDF]

				S. Liu, H. Wang, B. M. Currie, A. Molinolo, H. J. Leung, M. Moayeri, J. R. Basile, R. W. Alfano, J. S. Gutkind, A. E. Frankel, et al. Matrix Metalloproteinase-activated Anthrax Lethal Toxin Demonstrates High Potency in Targeting Tumor Vasculature J. Biol. Chem., January 4, 2008; 283(1): 529 - 540. [Abstract] [Full Text] [PDF]

				J. H. Sampson, G. Akabani, G. E. Archer, M. S. Berger, R. E. Coleman, A. H. Friedman, H. S. Friedman, K. Greer, J. E. Herndon II, S. Kunwar, et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors Neuro-oncol, January 1, 2008; 10(3): 320 - 329. [Abstract] [Full Text] [PDF]

				J. Wykosky, D. M. Gibo, and W. Debinski A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells Mol. Cancer Ther., December 1, 2007; 6(12): 3208 - 3218. [Abstract] [Full Text] [PDF]

				Y. Zhang, L. Xiang, R. Hassan, and I. Pastan Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors PNAS, October 23, 2007; 104(43): 17099 - 17104. [Abstract] [Full Text] [PDF]

				B. S. Mann, J. R. Johnson, M. H. Cohen, R. Justice, and R. Pazdur FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma Oncologist, October 1, 2007; 12(10): 1247 - 1252. [Abstract] [Full Text] [PDF]

				E. Olsen, E. Vonderheid, N. Pimpinelli, R. Willemze, Y. Kim, R. Knobler, H. Zackheim, M. Duvic, T. Estrach, S. Lamberg, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) Blood, September 15, 2007; 110(6): 1713 - 1722. [Abstract] [Full Text] [PDF]

				R. Hassan, S. Bullock, A. Premkumar, R. J. Kreitman, H. Kindler, M. C. Willingham, and I. Pastan Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers Clin. Cancer Res., September 1, 2007; 13(17): 5144 - 5149. [Abstract] [Full Text] [PDF]

				E. A. Olsen, Y. H. Kim, T. M. Kuzel, T. R. Pacheco, F. M. Foss, S. Parker, S. R. Frankel, C. Chen, J. L. Ricker, J. M. Arduino, et al. Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma J. Clin. Oncol., July 20, 2007; 25(21): 3109 - 3115. [Abstract] [Full Text] [PDF]

				M. G. Bernengo, P. Quaglino, A. Comessatti, M. Ortoncelli, M. Novelli, F. Lisa, and M. T. Fierro Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients Haematologica, June 1, 2007; 92(6): 784 - 794. [Abstract] [Full Text] [PDF]

				Y. H. Kim, M. Duvic, E. Obitz, R. Gniadecki, L. Iversen, A. Osterborg, S. Whittaker, T. M. Illidge, T. Schwarz, R. Kaufmann, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma Blood, June 1, 2007; 109(11): 4655 - 4662. [Abstract] [Full Text] [PDF]

				M.-F. Demierre, P. Ferzli, and D. Miller Measuring HRQOL in Patients With Cutaneous T-Cell Lymphoma Undergoing Therapy With Oral Bexarotene and Extracorporeal Photopheresis Arch Dermatol, May 1, 2007; 143(5): 659 - 661. [Full Text] [PDF]

				M. Duvic, R. Talpur, X. Ni, C. Zhang, P. Hazarika, C. Kelly, J. H. Chiao, J. F. Reilly, J. L. Ricker, V. M. Richon, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood, January 1, 2007; 109(1): 31 - 39. [Abstract] [Full Text] [PDF]

				J B Ruddle, C A Harper, D Honemann, J F Seymour, and H M Prince A denileukin diftitox (Ontak) associated retinopathy? Br J Ophthalmol, August 1, 2006; 90(8): 1070 - 1071. [Full Text] [PDF]

				F. Ghori, K. D. Polder, L. C. Pinter-Brown, A. O. Hoff, R. F. Gagel, S. I. Sherman, and M. Duvic Thyrotoxicosis after Denileukin Diftitox Therapy in Patients with Mycosis Fungoides J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2205 - 2208. [Abstract] [Full Text] [PDF]

				A. Molina, J. Zain, D. A. Arber, M. Angelopolou, M. O'Donnell, J. Murata-Collins, S. J. Forman, and A. Nademanee Durable Clinical, Cytogenetic, and Molecular Remissions After Allogeneic Hematopoietic Cell Transplantation for Refractory Sezary Syndrome and Mycosis Fungoides J. Clin. Oncol., September 1, 2005; 23(25): 6163 - 6171. [Abstract] [Full Text] [PDF]

				F. Foss, M. F. Demierre, and G. DiVenuti A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma Blood, July 15, 2005; 106(2): 454 - 457. [Abstract] [Full Text] [PDF]

				M.-F. Demierre, A. Tien, and D. Miller Health-Related Quality-of-Life Assessment in Patients With Cutaneous T-Cell Lymphoma Arch Dermatol, March 1, 2005; 141(3): 325 - 330. [Abstract] [Full Text] [PDF]

				J. H. Sampson, D. A. Reardon, A. H. Friedman, H. S. Friedman, R. E. Coleman, R. E. McLendon, I. Pastan, and D. D. Bigner Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: Case study Neuro-oncol, January 1, 2005; 7(1): 90 - 96. [Abstract] [PDF]

				S. Shulga-Morskoy and B.E. Rich Bioactive IL7-diphtheria fusion toxin secreted by mammalian cells Protein Eng. Des. Sel., January 1, 2005; 18(1): 25 - 31. [Abstract] [Full Text] [PDF]

				G S Harrison, M E Wierman, T M Nett, and L M Glode Gonadotropin-releasing hormone and its receptor in normal and malignant cells Endocr. Relat. Cancer, December 1, 2004; 11(4): 725 - 748. [Abstract] [Full Text] [PDF]

				R. J. Kreitman Confirmation and prevention of targeted toxicity by a recombinant fusion toxin Mol. Cancer Ther., December 1, 2004; 3(12): 1691 - 1692. [Full Text] [PDF]

				N. H. Dang, F. B. Hagemeister, B. Pro, P. McLaughlin, J. E. Romaguera, D. Jones, B. Samuels, F. Samaniego, A. Younes, M. Wang, et al. Phase II Study of Denileukin Diftitox for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma J. Clin. Oncol., October 15, 2004; 22(20): 4095 - 4102. [Abstract] [Full Text] [PDF]

				D. Jones, S. Ibrahim, K. Patel, R. Luthra, M. Duvic, and L. J. Medeiros Degree of CD25 Expression in T-Cell Lymphoma Is Dependent on Tissue Site: Implications for Targeted Therapy Clin. Cancer Res., August 15, 2004; 10(16): 5587 - 5594. [Abstract] [Full Text] [PDF]

				V. T. Ho, D. Zahrieh, E. Hochberg, E. Micale, J. Levin, C. Reynolds, S. Steckel, C. Cutler, D. C. Fisher, S. J. Lee, et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation Blood, August 15, 2004; 104(4): 1224 - 1226. [Abstract] [Full Text] [PDF]

				E. T.H. Yeh, A. T. Tong, D. J. Lenihan, S. W. Yusuf, J. Swafford, C. Champion, J.-B. Durand, H. Gibbs, A. A. Zafarmand, and M. S. Ewer Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management Circulation, June 29, 2004; 109(25): 3122 - 3131. [Abstract] [Full Text] [PDF]

				R. L. Piekarz, R. W. Robey, Z. Zhan, G. Kayastha, A. Sayah, A. H. Abdeldaim, S. Torrico, and S. E. Bates T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance Blood, June 15, 2004; 103(12): 4636 - 4643. [Abstract] [Full Text] [PDF]

				M. Girardi, P. W. Heald, and L. D. Wilson The Pathogenesis of Mycosis Fungoides N. Engl. J. Med., May 6, 2004; 350(19): 1978 - 1988. [Full Text] [PDF]

				T. M. Allen and P. R. Cullis Drug Delivery Systems: Entering the Mainstream Science, March 19, 2004; 303(5665): 1818 - 1822. [Abstract] [Full Text] [PDF]

				O. Murillo, A. Arina, I. Tirapu, C. Alfaro, G. Mazzolini, B. Palencia, A. L.-D. De Cerio, J. Prieto, M. Bendandi, and I. Melero Potentiation of Therapeutic Immune Responses against Malignancies with Monoclonal Antibodies Clin. Cancer Res., November 15, 2003; 9(15): 5454 - 5464. [Abstract] [Full Text] [PDF]

				T. Maier, A. Tun-Kyi, A. Tassis, K.-P. Jungius, G. Burg, R. Dummer, and F. O. Nestle Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells Blood, October 1, 2003; 102(7): 2338 - 2344. [Abstract] [Full Text] [PDF]

				A. E. Frankel, D. R. Fleming, P. D. Hall, B. L. Powell, J. H. Black, C. Leftwich, and R. Gartenhaus A Phase II Study of DT Fusion Protein Denileukin Diftitox in Patients with Fludarabine-refractory Chronic Lymphocytic Leukemia Clin. Cancer Res., September 1, 2003; 9(10): 3555 - 3561. [Abstract] [Full Text] [PDF]

				P. W. Heald Memorials and Mandates for Cutaneous Lymphomas Arch Dermatol, July 1, 2003; 139(7): 926 - 928. [Full Text] [PDF]

				J. Lundin, H. Hagberg, R. Repp, E. Cavallin-Stahl, S. Freden, G. Juliusson, E. Rosenblad, G. Tjonnfjord, T. Wiklund, and A. Osterborg Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome Blood, June 1, 2003; 101(11): 4267 - 4272. [Abstract] [Full Text] [PDF]

				A.C. Church Clinical advances in therapies targeting the interleukin-2 receptor QJM, February 1, 2003; 96(2): 91 - 102. [Full Text] [PDF]

				R. Hassan, M. R. Lerner, D. Benbrook, S. A. Lightfoot, D. J. Brackett, Q.-C. Wang, and I. Pastan Antitumor Activity of SS(dsFv)PE38 and SS1(dsFv)PE38, Recombinant Antimesothelin Immunotoxins against Human Gynecologic Cancers Grown in Organotypic Culture in Vitro Clin. Cancer Res., November 1, 2002; 8(11): 3520 - 3526. [Abstract] [Full Text] [PDF]

				K. S. McGinnis, M. Shapiro, J. M. Junkins-Hopkins, M. Smith, S. R. Lessin, C. C. Vittorio, and A. H. Rook Denileukin Diftitox for the Treatment of Panniculitic Lymphoma Arch Dermatol, June 1, 2002; 138(6): 740 - 742. [Full Text] [PDF]

				D. Fan, S. Yano, H. Shinohara, C. Solorzano, M. Van Arsdall, C. D. Bucana, S. Pathak, E. Kruzel, R. S. Herbst, A. Onn, et al. Targeted Therapy against Human Lung Cancer in Nude Mice by High-Affinity Recombinant Antimesothelin Single-Chain Fv Immunotoxin Mol. Cancer Ther., June 1, 2002; 1(8): 595 - 600. [Abstract] [Full Text] [PDF]

				A. E. Frankel, B. L. Powell, P. D. Hall, L. D. Case, and R. J. Kreitman Phase I Trial of a Novel Diphtheria Toxin/Granulocyte Macrophage Colony-stimulating Factor Fusion Protein (DT388GMCSF) for Refractory or Relapsed Acute Myeloid Leukemia Clin. Cancer Res., May 1, 2002; 8(5): 1004 - 1013. [Abstract] [Full Text] [PDF]

				D. A. Vallera, C. Li, N. Jin, A. Panoskaltsis-Mortari, and W. A. Hall Targeting Urokinase-Type Plasminogen Activator Receptor on Human Glioblastoma Tumors With Diphtheria Toxin Fusion Protein DTAT J Natl Cancer Inst, April 17, 2002; 94(8): 597 - 606. [Abstract] [Full Text] [PDF]

				V. Sandor, S. Bakke, R. W. Robey, M. H. Kang, M. V. Blagosklonny, J. Bender, R. Brooks, R. L. Piekarz, E. Tucker, W. D. Figg, et al. Phase I Trial of the Histone Deacetylase Inhibitor, Depsipeptide (FR901228, NSC 630176), in Patients with Refractory Neoplasms Clin. Cancer Res., March 1, 2002; 8(3): 718 - 728. [Abstract] [Full Text] [PDF]

				J. M. Connors, E. D. Hsi, and F. M. Foss Lymphoma of the Skin Hematology, January 1, 2002; 2002(1): 263 - 282. [Abstract] [Full Text]

				D. G. Maloney, B. M. Sandmaier, S. Mackinnon, and J. A. Shizuru Non-Myeloablative Transplantation Hematology, January 1, 2002; 2002(1): 392 - 421. [Abstract] [Full Text]

				M. Duvic, K. Hymes, P. Heald, D. Breneman, A. G. Martin, P. Myskowski, C. Crowley, and R. C. Yocum Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial Results J. Clin. Oncol., May 1, 2001; 19(9): 2456 - 2471. [Abstract] [Full Text] [PDF]

				M. Duvic, A. G. Martin, Y. Kim, E. Olsen, G. S. Wood, C. A. Crowley, R. C. Yocum, and for the Worldwide Bexarotene Study Group Phase 2 and 3 Clinical Trial of Oral Bexarotene (Targretin Capsules) for the Treatment of Refractory or Persistent Early-Stage Cutaneous T-Cell Lymphoma Arch Dermatol, May 1, 2001; 137(5): 581 - 593. [Abstract] [Full Text] [PDF]

				J. P. Greer, M. C. Kinney, and T. P. Loughran Jr. T Cell and NK Cell Lymphoproliferative Disorders Hematology, January 1, 2001; 2001(1): 259 - 281. [Abstract] [Full Text] [PDF]